In re EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation
United States District Court, District of Kansas
MDL No. 2785
Teva Pharmaceutical Industries (“Teva”), the maker of the multiple sclerosis drug Copaxone, allegedly boosted the drug’s price tag from $17,000 to $73,000 per year—turning an already pricy medication into a completely inaccessible one for many. If you’re concerned that you’ve been paying too much for Copaxone, Keller Rohrback wants to hear from you.
